The Mitogen Activated Protein Kinase Kinase Kinase Kinase 1 pipeline drugs market research report outlays comprehensive information on the Mitogen Activated Protein Kinase Kinase Kinase Kinase 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Mitogen Activated Protein Kinase Kinase Kinase Kinase 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, and Undisclosed which include the indications Solid Tumor, Unspecified Cancer, and Unspecified. It also reviews key players involved in Mitogen Activated Protein Kinase Kinase Kinase Kinase 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Mitogen Activated Protein Kinase Kinase Kinase Kinase 1 pipeline targets constitutes close to 28 molecules. Out of which, approximately 27 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 5, 3, 2, 13, and 3 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Mitogen Activated Protein Kinase Kinase Kinase Kinase 1 overview
Mitogen-activated protein kinase 1 (MAPK1) is an enzyme that is also known as ERK2. It is a serine/threonine kinase that is an essential part of the MAP kinase signal transduction pathway. MAPK1 is involved in a variety of cellular processes, including proliferation, differentiation, transcription regulation, and development. MAPK1 is encoded by the MAPK1 gene in humans. MAPK1 and MAPK3/ERK1 are two MAPKs that play a key role in the MAPK/ERK cascade.
For a complete picture of Mitogen Activated Protein Kinase Kinase Kinase Kinase 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
